文献速递睡眠呼吸障碍咽喉与嗓音

舌下神经刺激与阻塞性睡眠呼吸暂停患者的心血管结局:一项随机临床试验

Hypoglossal Nerve Stimulation and Cardiovascular Outcomes for Patients With Obstructive Sleep Apnea: A Randomized Clinical Trial.
PubMed 文献 · JAMA Otolaryngol Head Neck Surg · 2024-01-01

这项双盲、假对照、随机交叉治疗试验在3个学术医疗中心开展,纳入60例已植入舌下神经刺激(HGNS)装置且依从性良好、临床优化的阻塞性睡眠呼吸暂停(OSA)成人患者,比较4周主动HGNS与4周假HGNS治疗对24小时动态血压、射血前间期(PEP)和血流介导舒张(FMD)的影响。结果显示主动与假治疗之间24小时收缩压、PEP和FMD均无显著差异。

要点

  • 主动与假HGNS治疗间24小时收缩压变化无显著差异(-0.18 mm Hg,95%CI -2.21至1.84)。
  • PEP(0.11毫秒,95%CI -5.43至5.66)和FMD(-0.17%,95%CI -1.88%至1.54%)亦无显著差异。
  • 符合方案集(n=20,定义为假与主动治疗间呼吸暂停低通气指数降低至少50%)中观察到主动与假治疗间差异较大。

核心结论

  • 在这项假对照HGNS随机临床试验中,主动与假HGNS治疗之间平均24小时收缩压及其他心血管指标无显著差异。
  • 可从本试验中汲取若干方法学教训,为未来的HGNS随机临床试验提供参考。

研究设计与样本

  • 双盲、假对照、随机交叉治疗试验,2018年至2022年在3个学术医疗中心开展。
  • 纳入已植入HGNS装置且依从、临床优化的成人OSA患者,排除HGNS植入前1年内曾有驾车时入睡者。
  • 共60例参与者,接受4周主动HGNS治疗和4周假HGNS治疗,顺序随机,每段4周结束时采集24小时动态血压监测(ABPM)、PEP和FMD值。
  • 主要结局为平均24小时收缩压变化,其他ABPM终点为探索性,PEP和FMD为共同次要终点。
  • 数据分析于2022年1月至9月进行。

主要发现

  • 参与者(n=60)平均(SD)年龄67.3(9.9)岁,平均(SD)体重指数28.7(4.6),男性38例(63%),基线平均(SD)呼吸暂停低通气指数33.1(14.9)次/小时。
  • 主动与假治疗间24小时收缩压无差异(主动治疗平均变化-0.18 mm Hg,95%CI -2.21至1.84)。
  • 主动与假治疗间PEP无差异(主动治疗平均变化0.11毫秒,95%CI -5.43至5.66)。
  • 主动与假治疗间FMD无差异(主动治疗平均变化-0.17%,95%CI -1.88%至1.54%)。
  • 符合方案集(n=20,定义为假与主动治疗间呼吸暂停低通气指数降低至少50%)中观察到主动与假治疗间差异较大。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出,可从本试验中汲取若干方法学教训,为未来的HGNS随机临床试验提供参考。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Sham-controlled trials are needed to characterize the effect of hypoglossal nerve stimulation (HGNS) therapy on cardiovascular end points in patients with moderate-severe obstructive sleep apnea (OSA). OBJECTIVE: To determine the effect of therapeutic levels of HGNS, compared to sham levels, on blood pressure, sympathetic activity, and vascular function. DESIGN, SETTING, AND PARTICIPANTS: This double-blind, sham-controlled, randomized crossover therapy trial was conducted from 2018 to 2022 at 3 separate academic medical centers. Adult patients with OSA who already had an HGNS device implanted and were adherent and clinically optimized to HGNS therapy were included. Participants who had fallen asleep while driving within 1 year prior to HGNS implantation were excluded from the trial. Data analysis was performed from January to September 2022. INTERVENTIONS: Participants underwent a 4-week period of active HGNS therapy and a 4-week period of sham HGNS therapy in a randomized order. Each 4-week period concluded with collection of 24-hour ambulatory blood pressure monitoring (ABPM), pre-ejection period (PEP), and flow-mediated dilation (FMD) values. MAIN OUTCOMES AND MEASURES: The change in mean 24-hour systolic blood pressure was the primary outcome, with other ABPM end points exploratory, and PEP and FMD were cosecondary end points. RESULTS: Participants (n = 60) were older (mean [SD] age, 67.3 [9.9] years), overweight (mean [SD] body mass index, calculated as weight in kilograms divided by height in meters squared, 28.7 [4.6]), predominantly male (38 [63%]), and had severe OSA at baseline (mean [SD] apnea-hypopnea index, 33.1 [14.9] events/h). There were no differences observed between active and sham therapy in 24-hour systolic blood pressure (mean change on active therapy, -0.18 [95% CI, -2.21 to 1.84] mm Hg), PEP (mean change on active therapy, 0.11 [95% CI, -5.43 to 5.66] milliseconds), or FMD (mean change on active therapy, -0.17% [95% CI, -1.88% to 1.54%]). Larger differences between active and sham therapy were observed in a per-protocol analysis set (n = 20) defined as experiencing at least a 50% reduction in apnea-hypopnea index between sham and active treatment. CONCLUSIONS AND RELEVANCE: In this sham-controlled HGNS randomized clinical trial, mean 24-hour systolic blood pressure and other cardiovascular measures were not significantly different between sham and active HGNS therapy. Several methodologic lessons can be gleaned to inform future HGNS randomized clinical trials. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03359096.

来源:JAMA Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Dedhia RC, Bliwise DL, Quyyumi AA, et al. Hypoglossal Nerve Stimulation and Cardiovascular Outcomes for Patients With Obstructive Sleep Apnea: A Randomized Clinical Trial. JAMA Otolaryngol Head Neck Surg. 2024. PMID: 38032624. doi:10.1001/jamaoto.2023.3756

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。